Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the
initiation of dosing in a single, multinational, placebo-controlled
clinical trial to evaluate the efficacy and safety of eculizumab (Soliris ® )
for the prevention of delayed graft function (DGF) after kidney
transplantation in adult patients who are at increased risk of DGF.
for Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation investment picks